BISProShares UltraShort Nasdaq Biotechnology
Seeks daily investment results that correspond to -2x the daily performance of the Nasdaq Biotechnology Index.
By ProShares · Launched 2010
Annual Cost
0.95%
#5,033 of 6,040 · expensive
Fund Size
$2M
#5,645 of 6,040 · small
Return (1Y)
-57.4%
Track Record
16 years
#763 of 6,040 · established
Performance
Total-return NAV · USDGrowth of $10,000
$5,492-45.1%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Inverse
Sector
Health careIndex tracked
Nasdaq Biotechnology Index
Holdings
By weightConcentration
synthetic exposure — holdings shown are derivatives collateral, not the fund's positions
Repurchase Agreement
32.8%
Repurchase Agreement
16.2%
Repurchase Agreement
16.2%
Repurchase Agreement
9.7%
Repurchase Agreement
9.7%
Repurchase Agreement
8.1%
Repurchase Agreement
6.5%
Repurchase Agreement
6.5%
Repurchase Agreement
3.2%
N/A
-3.5%
Asset allocation
Cash
199.9%
Other
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
43.3%High
Year-on-year price swings
Max drawdown
-96.5%Severe
Worst peak-to-trough loss
Sharpe (3Y)
-0.83Below average
Sortino (3Y)
-1.13Moderate downside risk
Listing
- Exchange
- NASDAQ Global Select Market
Full fund details
- Objective
- Seeks daily investment results that correspond to -2x the daily performance of the Nasdaq Biotechnology Index.
- Strategy
- Invests in derivatives to gain inverse leveraged exposure to the Nasdaq Biotechnology Index, which includes U.S. and non-U.S. biotechnology and pharmaceutical companies. The Fund aims for daily results that are two times the inverse of the Index's performance, rebalancing daily to maintain this target.
- Inception date
- April 6, 2010
- Fund family
- ProShares
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save BIS to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18